Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
After ZW171's exit, ZW251 enters the clinic.
The FDA will rule on a low dose of zongertinib in the summer.
US approval could mark the company's graduation to oncology.
Meanwhile, Tango tries again in PRMT5.
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
Halda, Accent and Vividion take more projects into phase 1.
